Radius Recycling, Inc. - Class A Common Stock (RDUS)
27.81
+14.15 (103.59%)
Radius Recycling Inc is a company focused on sustainable practices in the recycling industry
It specializes in the collection, processing, and repurposing of various recyclable materials, contributing to reducing waste and promoting environmental conservation. The company employs advanced technologies to enhance the efficiency of its recycling methods, aiming to transform discarded materials into valuable resources. Through its operations, Radius Recycling Inc not only supports local communities by promoting green initiatives but also plays a crucial role in the circular economy by ensuring that materials are reused and kept out of landfills.
Stay up-to-date with the latest market trends one hour before the close of the markets on Friday. Explore the top gainers and losers during today's session in our detailed report.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Radius Recycling, Inc. (NASDAQRDUS) to Toyota Tsusho America, Inc. for $30.00 per share in cash is fair to Radius shareholders.
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Radius Recycling reported lower first-quarter revenue of $656.54 million, missing consensus of $665.6 million. Nonferrous prices rose, offsetting weaker domestic steel conditions. Adjusted loss per share was $(1.33), missing consensus. The company declared a dividend of $0.1875 per share.
BOSTON, MA / ACCESSWIRE / January 2, 2025 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and related areas, announced today it has granted Pharmanovia the exclusive commercialization rights to abaloparatide, a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures. The licensing agreement covers markets in the Asia Pacific region, specifically China, Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau and the Philippines. Abaloparatide is marketed in the U.S. by Radius under the tradename TYMLOS®.
BOSTON, MA / ACCESSWIRE / December 9, 2024 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and related areas, announced today it has granted Theramex the exclusive commercialization rights to ELADYNOS® (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures, for Mexico, Canada, Israel, South Africa, and Russia. Theramex will also have the opportunity to commercialize ELADYNOS® in other agreed upon unpartnered regions. Abaloparatide is marketed in the U.S. by Radius under the tradename TYMLOS®.
U.S. equities were little moved on Tuesday as investors continued to assess the potential for interest rate cuts following the latest economic data and comments from Fed Chair Jerome Powell.
Market sentiment improved as Nasdaq gains record level. S&P 500 and Dow Jones also rose, while some sectors closed negatively. Fear & Greed Index at 48.1.
Regulatory Approvals For U.S. Steel Deal; BHP-Anglo American Deal Falls Through; U.S. GoldMining Sustainability Highlights And More: Thursday's Top Mining Stories
TYMLOS®demonstrated a lower incidence of hip fracture and non-vertebral fracture compared to teriparatide in women with osteoporosis 50 years and older (n=43,352) in this analysis of real-world data
